

Special Issue

Mechanisms of Melanoma Progression

Message from the Guest Editor

Melanoma progression, metastasis and drug resistance are not only driven by irreversible genetic instability, but also by reversible and functional reprogramming of signaling routes. PI3K, together with downstream dependent and/or converged routes, is able to mediate extra- or intra-transduction signals, leading to the initiation of tumor development, progression and resistance. The aim of this Special Issue is to update the current findings addressing the role of receptor and non-receptor tyrosine kinases in melanoma progression and treatment resistance.

Guest Editor

Dr. Mohamed Hassan

1. Research Laboratory of Surgery-Oncology, Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA
2. Institut National de la Santé et de la Recherche Médicale, S1121, University of Strasbourg, 67000 Strasbourg, France

Deadline for manuscript submissions

closed (1 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/185475

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)